Bopindolol in the treatment of moderate hypertension: a dose-response study.

Abstract

To determine the optimal antihypertensive dose of bopindolol, we performed a randomized double-blind study in parallel groups. After 15 days of placebo single-blind, 115 hypertensive patients received daily for 28 days one of 4 doses: 0 mg (placebo), 0.5 mg, 1.0 mg, 2.0 mg. The reduction of supine diastolic blood pressure (BP) did not exhibit the pattern of a dose-effect relationship. The effect of 0.5 mg belonged to the plateau of the dose-effect curve (P = 0.1, analysis of variance). The reduction of heart rate (HR) followed a typical dose-effect curve, with a plateau beginning with 1 mg (P = 0.02). A trend toward an increase in the incidence of side-effects with dosage was observed (P = 0.3). Thus, the optimal antihypertensive dose may be 0.5 mg or less. Previous studies not using parallel randomized groups suggested an antihypertensive dose ranging from 2 to 4 mg. This study confirms that the dose-effect curves of beta blockers on HR and BP are dissociated. The dose-effect curve of HR seems unsuitable for assessing the optimal antihypertensive dose of a beta blocker.

• Authors: P Moleur, J C Peyrieux, J Luciani, D David, J P Boissel
• Journal: Fundamental & clinical pharmacology (Fundam Clin Pharmacol) Vol. 2 Issue 5 Pg. 431-40 ( 1988) ISSN: 0767-3981 [Print] England
• PMID: 2906897 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Adrenergic beta-Antagonists
• Pindolol
• bopindolol

Topics

• Adrenergic beta-Antagonists (administration & dosage, adverse effects)
• Blood Pressure (drug effects)
• Clinical Trials as Topic
• Dose-Response Relationship, Drug
• Double-Blind Method
• Drug Tolerance
• Female
• Heart Rate (drug effects)
• Humans
• Hypertension (drug therapy, physiopathology)
• Male
• Middle Aged
• Pindolol (administration & dosage, adverse effects, analogs & derivatives)
• Random Allocation